GH · Guardant Health
AI read · Bad for GH
The AI's read
A Delaware federal judge ordered Guardant Health to pay a large judgment and imposed an ongoing 6% royalty on core products that accounted for roughly 90% of revenue during the period, and the court explicitly upheld the patents' validity—creating sustained financial and margin pressure. Administrative USPTO reviews remain but do not currently invalidate the patents, leaving material downside from continuing royalties and interest.